SCHEDULE: Canaan Partners Reduces Stake in Tyra Biosciences
Schedule 13G Amendment
Canaan Partners entities have updated their beneficial ownership in Tyra Biosciences, reporting a reduction in holdings to 1.4% of outstanding shares.
Summary
- Canaan XI L.P. and its general partner, Canaan Partners XI LLC, now beneficially own 750,000 shares of Tyra Biosciences, Inc. common stock.
- This holding represents approximately 1.4% of the 53,867,115 total outstanding shares as of February 25, 2026.
- Canaan 2020+ Co-Investment L.P. Series 7 and its general partner, Canaan Partners 2020+ Co-Investment LLC, no longer hold any shares of the issuer as of March 31, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory filing reflecting routine portfolio management by an institutional investor rather than a fundamental change in the company's business outlook.
Positives
- The filing confirms that the reporting entities maintain a continued, albeit reduced, investment in the company.
Negatives
- Canaan 2020+ Co-Investment L.P. Series 7 has completely exited its position in the company.
Risks
- Potential market perception of reduced institutional confidence due to the divestment by the co-investment series.
Future Outlook
No specific forward-looking guidance regarding the company's operations or future investment intentions was provided in this ownership disclosure.
Industry Context
StockSavvy.ai notes that institutional portfolio rebalancing is common in the biotechnology sector, particularly as venture capital firms reach the end of fund lifecycles or adjust risk exposure in clinical-stage companies.
Comparison to Industry Standards
- The reduction of stake to below 5% is a standard regulatory disclosure event for institutional investors.
- The divestment by a co-investment vehicle is consistent with typical venture capital exit strategies for mature portfolio holdings.
Stakeholder Impact
- Minor impact on shareholder base composition due to the reduction of institutional holdings.
Next Steps
- No further actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 02/25/2026 | Date used for total outstanding shares calculation. |
| 03/02/2026 | Date of Issuer's Annual Report on Form 10-K. |
| 03/31/2026 | Date of event requiring the filing. |
| 04/24/2026 | Date of signature and filing. |
Keywords
Tyra Biosciences, Canaan Partners, Schedule 13G, Institutional Ownership, Biotech, Equity Divestment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.